This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Heartfailure (HF) is a complex syndrome which leads to significant morbidity and mortality, poor quality of life and extremely high costs to healthcare systems worldwide. In this review, we aim to comprehensively describe the burden of HF from an LMIC perspective, based on the more recent available data.
Care for survivors after an acute attack of COVID-19 should include paying close attention to cardiovascular health and disease.Systematic Review RegistrationPROSPERO [CRD42022353965].
Initially discovered and developed by Orion Corporation in Finland, intravenous levosimendan is approved in 60 countries outside the United States for use in hospitalized patients with acutely decompensated heartfailure. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,
Heartfailure (HF) is one of the significant complications in patients with myocardial infarction (MI), leading to increased risk for cardiovascular morbidity and mortality. Common predictors include older age, prior hypertension, diabetes and atrial fibrillation. HFrEF is more commonly.
ObjectiveThe aim of this retrospective study was to evaluate the usefulness of non-contrast cardiac magnetic resonance imaging, including cine imaging, T1 and T2 mapping, and texture analysis for T1 mapping, for identifying etiologies of heartfailure (HF).MethodsForty-seven MethodsForty-seven patients with HF were examined using a 1.5T
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a severe and complex condition that evolves from unresolved pulmonary embolism, leading to fibrotic obstruction of pulmonary arteries, pulmonary hypertension, and potential right heartfailure.
The retrospective analysis of data from the MODERATO II study demonstrated that AVIM therapy significantly improved echocardiographic (Echo) markers of diastolic dysfunction, an important component in the development of heartfailure, in hypertensive patients. Advanced HeartFailure Cardiologist, Duke Health on Feb.
Barostim is the world’s first FDA-approved neuromodulation heartfailure device, which works by stimulating baroreceptors — natural sensors located in the wall of the carotid artery, according to CVRx. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heartfailure.
Getty Images milla1cf Thu, 05/16/2024 - 15:37 May 16, 2024 — People were more likely to develop a type of treatment-resistant hypertension when they experienced adverse effects of economic and social conditions that influence individual and group differences in health status, known as social determinants of health. Over a period of 9.5
Background Cancer survivors are at increased risk of heartfailure (HF). to 1.25), p=0.003) and hypertension (OR 0.95, 95% CI (0.92 Objectives This systematic review sought to investigate the relationship between cardiotoxic cancer therapies and HF during survivorship. to 0.99), p=0.047), age (OR 1.14, 95% CI (1.04
High blood pressure, also known as hypertension, is a common condition that affects millions of people worldwide. Often referred to as the silent killer, hypertension can quietly damage your heart and other vital organs over time. Hypertension is diagnosed when blood pressure consistently reads 130/80 mm Hg or higher.
Infection (75.47%, 160/212) and heartfailure (51.42%, 109/212) were common comorbidities. The independent risk factors for mortality included left ventricular ejection fraction (LVEF), pulmonary hypertension, and low-density lipoprotein (LDL) levels (P<0.05).
What is the safety and utility of invasive implanted hemodynamic monitoring (IHM) using the CardioMEMS™ HF System in pediatric patients with heartfailure (HF) and pulmonary hypertension (PH)?
Heartfailure combined with hypertension is a major contributor for elderly patients (≥ 65 years) to in-hospital mortality. However, there are very few models to predict in-hospital mortality in such elderly p.
ABYSS suggests that long-term beta-blocker therapy is recommended after an MI, even in the absence of heartfailure, arrhythmia or uncontrolled hypertension.
We evaluated the prevalence of “heart stress” (HS) based on NT-proBNP cut-points proposed by the 2023 Consensus of the HeartFailure Association (HFA) of the European Society of Cardiology (ESC) in asymptomati.
Objectives Prognostic impact of lung ultrasound-derived B-lines (LUS-BL) in heartfailure with mildly reduced left ventricular ejection fraction (HFmrEF) patients remains elusive. Older age, hypertension (HR=2.06, 95% CI 1.31 We evaluated the correlation between LUS-BL and prognosis in HFmrEF patients.
6, 2025 Eko Health, a leader in applying artificial intelligence (AI) for the early detection of heart and lung diseases, recently announcedpublication of a peer-reviewed study evaluating its novel algorithm for the detection of pulmonary hypertension (PH). tim.hodson Mon, 02/10/2025 - 12:43 Feb.
Hypertension (HTN) and diabetes mellitus (DM) are two common comorbidities of heartfailure with reduced ejection fraction (HFrEF), each of which can cause right ventricular (RV) dysfunction. The aim of this s.
Recently, indisputable evidence has shown that the TyG index is strongly associated with cardiovascular disease [CVD, including atherosclerosis, heartfailure (HF), and hypertension] prognosis and mortality.
Pre-eclampsia and heartfailure have common risk factors, including hypertension, obesity and diabetes. It is not known whether heartfailure increases the risk of pre-eclampsia. This study examines whether pregestational heartfailure increases the risk of pre-eclampsia.
Hypertensive disorders of pregnancy as a risk factor for heartfailure. Hypertensive disorders of pregnancy (HDP) occur in almost 10% of gestations and preeclampsia, a more severe form, in 34%.
However, this comes at a cost with more women developing diabetes, hypertension and coronary artery disease as they age. These traditional cardiovascular risk factors not only increase their lifetime risk of heartfailure but also their overall risk of cancer. Women continue to enjoy a greater life expectancy than men.
American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines 2. New Study Published in JACC: HeartFailure Reveals that Despite Significant Efforts to Improve Acute HeartFailure Treatment Over the Past 20 Years, Management Remains Unchanged 3.
Methods and results TRED-HF was a randomized trial investigating heartfailure therapy withdrawal in patients with recovered DCM over 6months. The primary outcome was relapse defined as 10% reduction in left ventricular ejection fraction to 400ng/L, or clinical features of heartfailure.
These conditions have an increasing share in the health burden worldwide due to worsening endemic of hypertension, obesity, and diabetes. However, the same set of genes were significantly induced in the Trp53inp2-cKO hearts under both mechanical and metabolic stresses.
Heartfailure with preserved ejection fraction (HFpEF) is a widespread syndrome with limited therapeutic options and poorly understood immune pathophysiology.
Current guideline indications for intervention in asymptomatic patient are centred on left ventricular dimensions and ejection fraction and may include consideration in atrial fibrillation, pulmonary hypertension and those with left atrial dilatation.
Hypertension, Ahead of Print. In modeling, the risk for any cardiovascular disease event among women with a history of hypertensive disorders of pregnancy was generally 10% to 20% higher, with main models estimating hazard ratios to 1.20 (95% CI, 0.99–1.47) years for women with type 1 and 29.8 years for women with type 2 diabetes.
Hypertension, Ahead of Print. Epidemiological studies have revealed that hypertensiveheart disease is a major risk factor for heartfailure, and its heartfailure burden is growing rapidly.
In several conditions, including hypertension, systemic lupus erythematosus, and heartfailure, isolevuglandins (IsoLGs) are formed by lipid peroxidation and covalently bond with protein lysine residues. Thus, we have used a combined computational and experimental approach to define likely antigenic peptides in hypertension.
In this week’s View, Dr. Eagle looks at post-capillary pulmonary hypertension in heartfailure and the revised European guideline definition. He then explores obesity in adolescents and its impact on our societal health.
It looks like we might be able to add prediabetes and hypertension to the growing list of conditions that Eli Lilly’s “weight loss drug” tirzepatide is able to treat, after new analysis of the SURMOUNT-1 trial showed significant reductions in blood pressure and diabetes progression.
In the 1980s, when Stella Kourembanas, MD, began her career in neonatology, she cared for newborns with pulmonary hypertension, a disease that results in abnormally high blood pressure in the lung arteries and can lead to heartfailure. But pulmonary hypertension still persists.
BackgroundDespite the poor outcomes related to the presence of pulmonary hypertension, it often goes undiagnosed in part because of low suspicion and screening tools not being easily accessible such as echocardiography.
The significance of RNA modification in the pathogenesis of hypertension, cardiac hypertrophy, and atherosclerosis is well-established. This review examines the biological mechanisms and effects of RNA methylation in DCM and heartfailure. Of late, RNA methylation has garnered attention for its involvement in DCM.
However, it remains unclear whether hypertensive patients with long-term high AIP levels are at grea. The atherogenic index of plasma (AIP) has been shown to be positively correlated with cardiovascular events.
The idea that obesity increases the risk of heartfailure seems like an obvious conclusion. After all, as the Framingham Heart Study clearly showed, obesity and overweight are significantly associated with a higher risk of hypertension, angina and coronary heart disease.
Getty Images milla1cf Tue, 01/23/2024 - 13:38 January 23, 2024 — Sequana Medical NV , a pioneer in the treatment of fluid overload in liver disease, heartfailure and cancer, announced that an independent Data and Safety Monitoring Board (DSMB) approved the start of the randomized cohort in MOJAVE , the US Phase 1/2a study of DSR 2.0
ObjectiveClinical practice currently faces a significant shortfall in specific biomarkers needed for diagnosing right ventricular (RV) remodeling in patients with pulmonary hypertension (PH). ResultsPAB rats exhibited severe RV hypertrophy, fibrosis and enlargement of RV cardiomyocytes compared with sham group.
Hypertension, Ahead of Print. BACKGROUND:Diabetes is an important risk factor for heartfailure (HF) and is associated with left ventricular (LV) diastolic dysfunction. However, diabetic comorbid conditions, such as nocturnal hypertension, as predictors of diastolic dysfunction are not known in the absence of an HF period.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content